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Background: Graft hypertrophy is common after matrix-based autologous chondrocyte implantation (ACI) in the knee joint. How-
ever, it is not clear whether graft hypertrophy is a complication or an adjustment reaction in the cartilage regeneration after ACI.
Purpose: To analyze the cartilage quality of the ACI regeneration with graft hypertrophy using T2-weighted mapping.
Study Design: Cohort study; Level of evidence, 2.
Methods: A total of 91 patients with isolated cartilage defects (International Cartilage Repair Society [ICRS] grade III-IV) of the
knee were treated with Novocart 3D, a third-generation, matrix-based, ACI procedure in the knee joint. All patients were evaluated
with a standardized magnetic resonance imaging protocol after 3, 6, 12, 24, 36, and 48 months postoperatively. For morpholog-
ical and biochemical assessment, the T2-weighted relaxation times of the ACI grafts as well as the healthy surrounding cartilage
were determined. The results of the 20 patients with graft hypertrophy (hypertrophic group) were compared with the results of 21
matched patients without graft hypertrophy (nonhypertrophic group) after ACI. Match-paired analysis was performed by compar-
ison of age, defect size, and body mass index.
Results: The T2-weighted relaxation times of the ACI graft showed significant improvement, with values decreasing from 52.1
milliseconds to 33.3 milliseconds after 48 months. After 12 months, the T2-weighted relaxation times were constant and compa-
rable with the healthy surrounding cartilage. Graft hypertrophy was seen in 22% (n = 20) of the patients who underwent ACI. A
significant difference in T2-weighted relaxation times between the hypertrophic and nonhypertrophic ACI grafts could not be
found except after 36 months (hypertrophic T2-weighted relaxation time/nonhypertrophic T2-weighted relaxation time: 3 months,
48.0/56.4 ms, P = .666; 6 months, 45.6/42.5 ms, P = .280; 12 months, 39.3/34.7 ms, P = .850; 24 months, 34.8/32.2 ms, P = .742;
36 months, 34.6/38.2 ms, P = .030; 48 months, 34.2/32.3 ms, P = .693).
Conclusion: The T2-weighted relaxation time of the ACI graft cartilage showed significant improvements over the observation
period of 4 years postoperatively. After 2 years, graft maturation was completed. Graft hypertrophy after ACI was seen in
22% of the patients. Reduced cartilage quality could not be found in patients with graft hypertrophy after ACI.
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Autologous chondrocyte implantation (ACI) was estab-
lished in Sweden in the late 1980s by Brittberg and
others3,4 and published for the first time in 1994. In the
so-called first-generation ACI, a periosteal flap was used
to cover the implanted autologous chondrocytes. In sec-
ond-generation ACI, the chondrocytes were covered with
a collagenous flap. Currently, a matrix-based ACI
is most frequently used, which is referred to as third-
generation ACI. In matrix-based ACI, the chondrocytes
are seeded in a collagenous matrix and are then fixed in
the defected cartilage.
The majority (88.5%) of post-ACI complications, which
are determined by arthroscopy or magnetic resonance
imaging (MRI), can be divided into 4 groups: graft
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hypertrophy, poor healing of the ACI graft onto the sur-
rounding healthy cartilage, poor quality of the ACI graft,
and graft delamination.19
Graft hypertrophy after ACI in the knee joint was most
frequently observed in the first-generation ACI, which
used a periosteal flap for coverage.10,25 The use of the
second-generation ACI, which substituted the periosteal
flap with a type I or III collagen membrane, resulted in
a significant decrease in observed graft hypertrophy.8,12
This leads to the assumption that the periosteal flap is
the cause of graft hypertrophy. However, graft hypertro-
phy is still observed with third-generation ACI without
affecting the clinical outcome.26
The question arises whether there is a difference in car-
tilage quality between ACI grafts with or without graft
hypertrophy. To answer this question, we analyzed ACI
graft regeneration using MRI examinations and deter-
mined T2-weighted relaxation times with T2-weighted
mapping, which is an established method for the assess-
ment of cartilage quality.5,18,32 We performed a prospective
study, determining the T2-weighted relaxation times at
follow-up of 4 years after third-generation ACI with deter-
mination of the graft hypertrophy.
The aim of the present study was to assess cartilage
quality of the implanted ACI graft in the knee joint in
patients with graft hypertrophy. Our hypothesis was that
graft hypertrophy of matrix-based ACI has equal cartilage
quality in the T2-weighted relaxation time values com-
pared with the ACI graft without graft hypertrophy.
METHODS
Patients
With institutional review board approval, a total 91 patients
were included in this study, consisting of 39 women (42.9%)
and 52 men (57.1%). All patients were treated between
2004 and 2011 with Novocart 3D (TETEC AG), a third-
generation ACI. The ACI procedure and rehabilitation were
performed as described in a previous study.23 The inclusion
criteria were full-thickness cartilage defects of grades III or
IV according to the International Cartilage Repair Society
classification, defect size between 2 and 15 cm2, patient age
between 16 and 50 years, and intact menisci and ligaments
with a regular mechanical axis (\5malalignment). Patients
with osteoarthritis of the knee, joint instability, arthritis, cor-
responding chondral defects, or more than 2 focal cartilage
defects were excluded from the study.
Graft Hypertrophy
The radiological evaluation was performed with an MRI
examination of the knee using a 1.5-T device (Magnetom
Avanto, Sonata, Symphony; Siemens Medical Solutions).
The MRI examinations were conducted at 3, 6, 12, 24, 36,
and 48 months postoperatively based on a standardized
protocol including a proton density–weighted sequence
(Table 1). The data were collected using the software Syngo
(Siemens Medical Solutions).
To identify patients with hypertrophic ACI grafts, the
graft thickness was measured in a blinded fashion by an
experienced orthopaedic surgeon and a radiologist special-
izing in musculoskeletal assessment (T.N.).
The thickest areas of the ACI grafts were measured in 3
regions, and the thickness of the healthy surrounding car-
tilage was measured in the same manner. A mean value
was calculated from the 3 measurements. Subsequently,
the relative graft thickness was calculated as a ratio
between the ACI graft thickness and the thickness of the
healthy surrounding cartilage. This relative graft thick-
ness was used to classify graft hypertrophy according to
Kreuz et al15 (grade 1,\125%; grade 2,\150%; grade 3,
\200%; grade 4, .200%) (Figure 1). To compare the
results of the MRI evaluation of the hypertrophic group,
a matched-pair nonhypertrophic group was formed from
the database. The criteria for pairwise matching were
age, defect size (cm2), and body mass index (BMI; kg/m2).
The International Knee Documentation Committee
(IKDC) subjective evaluation form was used to evaluate
clinical outcomes.
T2-Weighted Relaxation Time
The acquired Digital Imaging and Communications in Med-
icine (DICOM) data sets were used to segment the cartilage
into 3 images. Articular cartilage was segmented in the fast
low-angle shot (FLASH) sequence by use of the in-house
software PaCaSe.13 After segmentation, the cartilage plate
TABLE 1
Overview of the MRI Examination Protocola
Sequences Time, min:s
1. PD TSE fs coronal 384 matrix 3:50
2. T1-weighted coronal 384 matrix 2:36
3. PD TSE fs sagittal 384 matrix 3:50
4. PD TSE fs axial 384 matrix 4:37
5. T1-weighted FLASH 3D WE sagittal 5:18
6. T2-weighted MAP coronal or axial 12:50
7. T1-weighted FLASH 3D WE coronal or axial 3:03
After injection of contrast agent:
8. T1-weighted coronal fs 384 matrix 2:36
9. T1-weighted axial fs 384 matrix 2:53
a3D, 3-dimensional; FLASH, fast low-angle shot; fs, fat satura-
tion; MRI, magnetic resonance imaging; PD, proton density; TSE,
turbo spin echo; WE, water excitation.
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was reconstructed 3-dimensionally with the overlay of the
segmentation sequences with the multiecho data sets. Man-
ual corrections were performed when the water excitation
sequences and the multiecho sequences differed due to
movement of the patients during MRI examination.
For the calculation of T2-weighted relaxation time, PMI
software was used.29 The segmented cartilage was subdi-
vided into 3 zones from the subchondral bone to the carti-
lage surface. Nine further subdivisions were made from
the medial to lateral border. A total of 27 regions of inter-
est, with 70 picture elements per region of interest for each
cartilage plate, were created. The T2-weighted relaxation
times were expressed as a mean value per segmentation
layer of the segmented 3 consecutive slices.
Statistical Analysis
The T2-weighted relaxation times at each time point were
assessed according to the age or the sex of the patient, graft
location, defect size, and hypertrophy grade by random
intercept models. These models were fitted with the
MIXED procedure of SAS version 9.2 for Linux (SAS Insti-
tute). The t test was used to compare the hypertrophic and
nonhypertrophic groups. To compare the T2-weighted
relaxation times at different control points, nonparametric
tests were used depending on the sample. For independent
samples, the Whitney U test was used. The Wilcoxon test
was used in connected samples. The tests were carried
out with IBM SPSS Statistics 21. The level of statistical
significance was set at P\ .05.
RESULTS
The mean patient age was 34.4 years (SD, 12.2 years). The
mean BMI was 25.9 kg/m2 (SD, 4.3 kg/m2). The cartilage
defects had a mean size of 5.4 cm2 (SD, 2.6 cm2) (Table
2). The location of the cartilage defects was at the medial
femoral condyle (n = 44, 48%), lateral femoral condyle
(n = 6, 7%), and patella (n = 41, 45%). Two patients missed
the 3-month follow-up and 1 patient the 6-month follow-up.
No one missed the 12-month follow-up. Two patients
missed the 24-month follow-up, 7 patients the 36-month
follow-up, and 8 patients the 48-month follow-up.
Graft Hypertrophy
The development of graft hypertrophy was found on MRI
examination of 20 patients (the hypertrophic group). This
corresponds to a total graft hypertrophy rate of 22%. In 12
patients (60%), the affected graft was located at the medial
femoral condyle (n = 10; 50%) and lateral femoral condyle
(n = 2; 10%). In 8 patients (40%), graft hypertrophy occurred
in the medial patella (5; 25%) and lateral patella (3; 15%).
New occurrences of graft hypertrophy were found up to
24 months postoperatively. Fifteen patients (75%) devel-
oped graft hypertrophy in the first year after ACI. In 5
patients (25%), a new graft hypertrophy could be detected
24 months postoperatively.
In the hypertrophic group, 75% (n = 15) of patients had
grade 1 graft hypertrophy. In 25% of patients (n = 5), grade
2 graft hypertrophy was detected. A de novo development of
grade 3 graft hypertrophy was not observed. One patient
(5%) who had a grade 2 graft hypertrophy after 12 months
went on to develop a grade 3 graft hypertrophy after 24
months. After 36 months postoperatively, this patient had
a grade 1 graft hypertrophy. The individual parameters
analyzed (BMI, age, sex, and defect size/localization) were
not found to influence the occurrence of graft hypertrophy.
Relative Graft Thickness
In the observed postoperative course of 4 years, we found
a significant difference in the development of graft thick-
ness of the ACI grafts in patients with graft hypertrophy
(n = 20; 22%) and those without graft hypertrophy (n =
21; 78%). In the first MRI follow-up after 3 months, no rel-
evant difference was found between the hypertrophic (94%
relative graft thickness compared with the healthy sur-
rounding cartilage) and the nonhypertrophic ACI grafts
(86%). After 24 months, a significant difference was
detected (P = .005). The hypertrophic group had a maxi-
mum mean graft thickness of 124%, with a total increase
in graft thickness of 32% in the postoperative course. In
comparison, the nonhypertrophic group had a graft thick-
ness of 90% after 24 months (Table 3).
In the following course after 24 months, we found
decreasing graft thickness with normalization at the end
of the observation period. A significant difference between
Figure 1. Determination of relative graft thickness of the
autologous chondrocyte implantation (ACI) grafts at the
femur in a T1-weighted, fast low-angle shot, 3-dimensional
sagittal sequence. Green shading, ACI graft; yellow shading,
healthy surrounding cartilage.
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the hypertrophic group and the nonhypertrophic group
was found after 24 months. The nonhypertrophic group
showed no relevant change of the graft thickness during
the entire observation period (Figure 2).
Clinical Evaluation
The patients included in our study showed significantly
higher IKDC scores after 6, 12, 24, 36, and 48 months post-
operatively compared with the preoperative findings. The
mean IKDC score was 38.2 (SD, 22.2; range, 2.3-99.6). The
mean IKDC score increased to 59.8 (SD, 22.0; range, 13.8-
93.1) after 48 months. We found no significant differences
in IKDC scores between the hypertrophic group (preopera-
tive, 37.4; 6 months, 49.9; 12 months, 51.2; 24 months,
55.1; 36 months, 51.6; 48 months, 56.4) and the nonhypertro-
phic group (preoperative, 39.1; 6 months, 51.2; 12 months,
57.1; 24 months, 59.6; 36 months, 59.9; 48 months, 61.9) dur-
ing the course of the entire observation period (preoperative,
P = .728; 6 months, P = .830; 12 months, P = .393; 24 months,
P = .558; 36 months, P = .207; 48 months, P = .484).
T2-Weighted Relaxation Time
The T2-weighted relaxation times of all ACI grafts were
52.1 milliseconds after 3 months. In the course of the
study, we detected a significant reduction of T2-weighted
relaxation time by 36%—to 33.3 milliseconds—after 48
months (P = .000) compared with the T2-weighted relaxa-
tion time after 3 months (Table 4).
In a matched-pair analysis, we analyzed the T2-
weighted relaxation times of the hypertrophic grafts (n =
20) and the nonhypertrophic grafts (n = 21). No significant
difference (P . .05) between the hypertrophic and the non-
hypertrophic grafts was found after 6, 12, and 24 months
(Table 5).
After 36 months, a significant difference was found (P =
.03). However, this difference was not noticeable after 48
months. At the end of the follow-up, an absolute difference
of the T2-weighted relaxation time of 1.9 milliseconds was
found in the comparison of the two groups, without signif-
icant difference between the two groups (Figure 3). No cor-
relation was found regarding the T2-weighted relaxation
times and the grade of graft hypertrophy.
DISCUSSION
The most important finding of the present study was that
graft hypertrophy after third-generation ACI is a transient
phenomenon, as we noted equal T2-weighted relaxation
times compared with the nonhypertrophic ACI grafts
over the observation period of 4 years. Graft hypertrophy
can therefore be seen as an adjustment reaction after
third-generation ACI.
TABLE 2
Overview of the Patient Collectivea
Entire Patient Collective Hypertrophic Group Nonhypertrophic Group
No. of patients 91 20 21
Body mass index, kg/m2 25.9 6 4.3
(19.0-38.3)
24.7 6 3.9
(19.0-32.1)
26.3 6 4.5
(19.6-35.3)
Age, years 34.4 6 12.2
(11-66)
33.7 6 12.9
(12.0-57.8)
35.2 6 12.3
(17.3-66.0)
Defect size, cm2 5.4 6 2.6
(2.0-15.0)
5.8 6 2.7
(2.0-15.0)
5.3 6 2.9
(4.0-12.0)
aAll values except for number of patients are expressed as mean 6 SD (range).
TABLE 3
Overview of the Development of Relative Graft Thickness
in the Hypertrophic and Nonhypertrophic Groups
Follow-up Hypertrophic Groupa Nonhypertrophic Groupa
3 months 94 89
6 months 106 90
12 months 119 89
24 months 124 90
36 months 120 88
48 months 116 89
aValues for relative graft thickness are expressed as percentage
of the healthy surrounding cartilage.
70
80
90
100
110
120
130
3 months 6 months 12 months 24 months 36 months 48 months
Re
la
v
e 
Gr
a
 T
hi
ck
ne
ss
 in
 %
Figure 2. Development of relative graft thickness in the
hypertrophic (top line) and nonhypertrophic (bottom line)
groups.
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Graft hypertrophy after ACI is often observed in the
postoperative course and is seen as a potential cause of
postoperative pain, which can lead to an operative revision
surgery. In previous studies, no worse clinical results were
observed in patients with graft hypertrophy after third-
generation ACI.26,34 These results could be confirmed by
the findings of the present study. However, less knowledge
is available about the cartilage quality of the ACI grafts in
patients with graft hypertrophy. For the first time, we ana-
lyzed hypertrophic ACI grafts with T2-weighted relaxation
times in a 4-year observation.
In the present prospective study, a radiological evalua-
tion of the implanted, cell-seeded collagenous scaffolds
was carried out with standardized MRI examination in
TABLE 4
Overview of the T2-Weighted Relaxation Times of All ACI Grafts and the Healthy Surrounding Cartilage
Follow-up All ACI Graftsa All Healthy Surrounding Cartilagea P Value
3 months 52.1 6 18.5 33.2 6 6.9 .018b
6 months 44.1 6 13.0 31.8 6 4.8 .020b
12 months 37.1 6 8.0 31.0 6 4.7 .098
24 months 33.6 6 7.3 31.4 6 5.1 .163
36 months 36.4 6 10.6 29.9 6 5.5 .825
48 months 33.3 6 8.2 31.6 6 3.3 .300
aValues expressed in milliseconds as mean 6 SD. ACI, autologous chondrocyte implantation.
bAfter 12 months, no significant differences between the ACI grafts and the healthy surrounding cartilage were found.
TABLE 5
T2-Weighted Relaxation Times of the Autologous Chondrocyte Implantation Grafts
in the Hypertrophic and Nonhypertrophic Groups
Follow-up Hypertrophic Groupa Nonhypertrophic Groupa P Value
3 months 48.0 6 18.4 56.4 6 18.2 .666
6 months 45.6 6 16.3 42.5 6 8.6 .280
12 months 39.3 6 8.3 34.7 6 7.3 .850
24 months 34.8 6 7.7 32.2 6 7.0 .742
36 months 34.6 6 5.7 38.2 6 13.9 .03b
48 months 34.2 6 7.4 32.3 6 9.1 .693
aValues expressed in milliseconds as mean 6 SD.
bAfter 36 months, a significant difference was found (P = .03). However, this difference was not noticeable after 48 months.
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All ACI Gras Hypertrophic Nonhypertrophic Healthy Surrounding Carlage
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__
Figure 3. Development of T2-weighted relaxation times (ms) in all autologous chondrocyte implantation (ACI) grafts, in hypertro-
phic and nonhypertrophic groups. After 3 and 6 months, significantly different T2-weighted relaxation times were found compared
with the healthy surrounding cartilage (*P \ .005). After 6 months, no significant differences were observed. No differences
between the hypertrophic and nonhypertrophic grafts were found after 3, 6, 12, 24, and 48 months. After 36 months, a difference
was observed with a temporary increase in the T2-weighted relaxation times of the nonhypertrophic group (line).
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postoperative follow-up. For comparative reasons, all
patients were treated with the same third-generation
ACI product (Novocart 3D).
MRI examination after ACI is an established and suit-
able method for analyzing the healing of ACI grafts for car-
tilage regeneration.7,14,28 The T2-weighted relaxation time
is a complex method for quantitative analysis of ACI carti-
lage maturation and has been used in previous stud-
ies.22,27,31 To identify patients with graft hypertrophy, we
measured the relative graft thickness according to the
method established by Kreuz et al.15
For the assessment of hyaline articular cartilage, bio-
chemical MRI (eg, T2-weighted relaxation time) is a more
sensitive method for detecting chondral lesions than con-
ventional magnetic resonance tomography.9 Determina-
tion of T2-weighted relaxation time and the use of
T2-weighted mapping are already regularly used in the
context of cartilage repair procedures.5,6,18,22,27
The incidence of graft hypertrophy in the present study
was 22%. Previous studies have found similar incidences of
graft hypertrophy. Zak et al34 found an incidence of 24%
after 6 months. In another study, the graft hypertrophy
incidence in patients with third-generation ACI was
27%.21 The incidence of graft hypertrophy in other studies
in the literature has ranged from 9% to 40%.1,17,35 All
observed graft hypertrophies occurred within 24 months
after the operation; 75% of the diagnosed graft hypertro-
phies occurred in the first year postoperatively.
Our detailed analysis of hypertrophic and nonhypertro-
phic patients shows that the hypertrophic patients had
a significant increase in graft thickness after 12 to 24
months. The nonhypertrophic grafts, however, showed no
additional growth between 12 and 24 months. After this
period, the relative graft thickness declined in the hyper-
trophic group.
In this study, a majority of cases of graft hypertrophy
were grades 1 and 2. Clinical results in the literature did
not show worse outcomes.30,34 A grade 3 graft hypertrophy
was observed in only 1 patient in the current study, and no
revision surgery was performed. No cases of grade 4 graft
hypertrophy were observed. In previous studies, more cases
with a higher grade of graft hypertrophy have been observed
with the use of a periosteal flap (Kreuz et al15: grade 1,
20.7%; grade 2, 37.9%; grade 3, 24.1%; grade 4, 10.3%).
The causes for graft hypertrophy after ACI remain
unclear. Previously, osteochondritis dissecans and acute
trauma were seen as risk factors.30 Henderson et al11
observed a possible influence of the defect size and graft
localization in first-generation ACI using a periosteal
flap. It was thought that the BMI, the patient’s age or
sex, the defect size, and the defect location (femoral con-
dyle/patella) were risk factors that could lead to the devel-
opment of graft hypertrophy in the postoperative course. In
the present study, we found no influence of the analyzed
parameters (BMI, age, sex, and defect size/localization)
on the occurrence of graft hypertrophy.
We suggest that the cause of graft hypertrophy after
third-generation ACI without periosteal flap seems to be
intrinsic. Li et al16 found that static compressive stress
had a relevant influence on chondrocyte proliferation in
vitro, which possibly may influence graft hypertrophy after
cartilage repair procedures. The assumption that graft
hypertrophy is a temporary adaptation process might be
affirmed by the results of our study. At the end of the
observation period, we found a mild relative graft hyper-
trophy of 116% in the hypertrophic group without com-
plaints, which supports this assumption.
The T2-weighted values for healthy cartilage and carti-
lage transplants were measured postoperatively between
30 and 34 milliseconds for 24 to 48 months, parameters
which were described by Dunn et al5 and Nissi et al.24
One major finding of this study is that we did not find a sig-
nificant difference in the T2-weighted relaxation times
between hypertrophic and nonhypertrophic ACI grafts
over the course of the entire observation period. We found
no evidence for different amounts of collagen, a different
collagen fiber course, or increased water content in hyper-
trophic ACI grafts compared with nonhypertrophic ACI
grafts. Only once, after 36 months, was a temporary differ-
ence detected between the hypertrophic and the nonhyper-
trophic groups. The single, observed significant difference
of the T2-weighted relaxation time might have been caused
by the increased thickness of the hypertrophic group before
36 months with an intermediate content of water of the
hypertrophic grafts. After 36 months, no significant differ-
ences were observed, suggesting that the overwhelming
growth of the hypertrophic grafts had ended.
This observation coincides with the published results of
Niemeyer et al.20 In their case report, no significant differ-
ence could be found in the histological analysis of a hyper-
trophic ACI graft of a 49-year-old female patient. The
authors concluded that graft hypertrophy did not cause
histological changes with hypertrophic chondrocytes.
A defective collagen network, which can be assessed
with T2-weighted relaxation time, is an indicator of defec-
tive cartilage tissue.33 Increased T2-weighted relaxation
times for the ACI grafts were seen in general at the begin-
ning of the maturation process, about 6 months after the
ACI procedure. A completed maturation process can be
found by an adjustment of the T2-weighted relaxation
times between the ACI grafts and healthy surrounding
cartilage.
For both groups (hypertrophic and nonhypertrophic),
we showed an adjustment of the T2-weighted relaxation
times in the postoperative course with decreasing standard
deviation from 18 milliseconds after 3 months to 7 millisec-
onds after 48 months postoperatively. This corresponds to
a homogenization of the T2-weighted relaxation times in
the analyzed groups. This assumption is in agreement
with the findings of previous studies.22
Breinan et al2 observed a proliferation of chondrocytes
in rabbits during the first 3 months after cartilage cell
implantation. A significant difference in T2-weighted
relaxation times between the ACI grafts and the healthy
surrounding cartilage was seen up to 6 months postopera-
tively in the current study. Through these findings, we
hypothesize that the maturation of the ACI grafts is not
completed before 12 months.
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One limitation of the study is the lack of histological
biopsy specimens of the ACI grafts. An additional histolog-
ical analysis would improve the results of this study. This
analysis could confirm the measurements of T2-weighted
relaxation time. Furthermore, it would be interesting to
get more information about the cartilage structure and
content of problematic ACI graft therapies, such as those
that entail graft hypertrophy or postoperative pain.
CONCLUSION
The analysis of T2-weighted relaxation times of all ACI
graft cartilage shows significant improvements during
the postoperative observation time of 4 years. The T2-
weighted relaxation times of the ACI grafts showed similar
values compared with normal hyaline cartilage after 12 to
24 months. Graft hypertrophy after matrix-based ACI was
seen in 22% of the patients. No differences in T2-weighted
relaxation times could be found between patients with or
without graft hypertrophy after ACI. Graft hypertrophy
seems to be an adjustment reaction that declined in the
postoperative course without operative intervention.
Hypertrophic ACI grafts show no worse cartilage quality
compared with regular ACI grafts.
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